Full Press Release Details
IDEAYA Biosciences Announces Clinical Program Updates for IDE397 a Potential First in Class Phase 2 MAT2A Inhibitor Targeting MTAP Deletion Solid Tumors.
IDYA
IDEAYA Biosciences Announces Clinical Program Updates for IDE397 a Potential First in Class Phase 2 MAT2A Inhibitor Targeting MTAP Deletion Solid Tumors
Key Takeaway: IDEAYA Biosciences Announces Clinical Program Updates for IDE397 a Potential First in Class Phase 2 MAT2A Inhibitor Targeting MTAP Deletion Solid Tumors
Price reaction · baseline $36.99 (2024-06-21 close) · 2 other IDYA headline(s) in the window, move may be shared
day 0 close
0%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+47%
120-day peak, hindsight
Typical move
5.2%
average across 6 past catalysts
Cash runway
~42 mo
Minimal dilution risk
Lead asset
IDE892
Phase 1 · NSCLC Adenocarcinoma